OP0067 SEX DIFFERENCES IN PERCEPTIONS OF PSORIATIC ARTHRITIS DISEASE IMPACT, MANAGEMENT AND PHYSICIAN INTERACTIONS: RESULTS FROM A GLOBAL PATIENT SURVEY
Authors: L. Eder, P. Richette, L. Coates, V. F. Azevedo, J. C. Cappelleri, M. Hoang, J. Moser, C. Kinch, M. Kessouri
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Women with psoriatic arthritis (PsA) have more severe disease activity and lower health-related quality of life vs men.<sup>[1]</sup> <h3>Objectives</h3> To assess sex differences in disease impact perceptions and physician interactions with patients (pts) with PsA using global survey data. <h3>Methods</h3> An online survey by The Harris Poll (2 Nov 2017–12 Mar 2018) included 1286 pts from 8 countries, aged ≥18 years, who had PsA for &gt;1 year, visited a rheumatologist/dermatologist in the past 12 months and had used ≥1 disease-modifying antirheumatic drug (DMARD) for PsA.<sup>[2]</sup> Results were stratified post hoc by sex; analysed descriptively and by binomial (chi-squared) tests. Percentages/binomial tests of the final global data were adjusted for size of each country's adult population. Statistically significant differences (p&lt;0.05) were described as more/higher. <h3>Results</h3> 52% of pts were female; 24% from Europe (France/Spain/UK). Mean age of females/males (41.3/41.0 years) and time since diagnosis (9.2/8.8 years) were similar. More females had anxiety (32% vs 24%), osteoarthritis (17% vs 9%), had taken a steroid (57% vs 43%) and were taking any DMARD (biologic and oral DMARDs; 20% vs 15%). More females vs males reported a major/moderate negative PsA impact on physical activity (81% vs 75%) and emotional/mental well-being (73% vs 65%); major/moderate impact on other life aspects, such as work productivity, was similar between sexes (Figure 1). More females vs males reported the following because of PsA: emotional distress (65% vs 50%), stopped social activities (49% vs 41%) and went on permanent work disability (14% vs 9%); more males vs females reported lower work productivity (47% vs 38%) because of PsA. Switching treatment due to joint symptoms (41% vs 28%) and side effects (35% vs 22%) were higher in females vs males; switching due to potential serious side effect concerns (29% vs 16%) and symptoms being under control (18% vs 9%) were higher in males vs females. More females vs males were very satisfied with their rheumatologist's communication (60% vs 51%), and discussed treatment goals (83% vs 78%), impact on ability to conduct daily activities (82% vs 73%) and response to and/or satisfaction with treatment regimen (81% vs 72%; Table 1). Pt ability to describe their PsA diagnosis/recall symptoms may limit the study. <h3>Conclusion</h3> More women vs men reported a major/moderate PsA impact on physical and emotional/mental well-being. More women were very satisfied with communication and discussed treatment goals with their rheumatologist. It is important to consider how sex impacts a pt's experience with PsA. <h3>References</h3> [1]Orbai et al. Arthritis Care Res (Hoboken) 2020; 72: 1772-9 [2]Coates et al. Health Qual Life Outcomes 2020; 18: 173 <h3>Acknowledgements</h3> This study was sponsored by Pfizer. Medical writing support, under the direction of the authors, was provided by Lewis C Rodgers, PhD, CMC Connect, a division of IPG Health Medical Communications, and was funded by Pfizer, New York, NY, USA, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022; 175: 1298-1304). <h3>Disclosure of Interests</h3> Lihi Eder Consultant of: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer Inc and UCB, Grant/research support from: AbbVie, Eli Lilly, Fresenius Kabi, Janssen, Novartis, Pfizer Inc, Sandoz and UCB, Pascal Richette Speakers bureau: AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer Inc and UCB, Consultant of: AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer Inc and UCB, Laura Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead Sciences, GSK, Janssen, Medac, Novartis, Pfizer Inc and UCB, Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, MoonLake, Novartis, Pfizer Inc and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc and UCB, Valderilio F Azevedo Speakers bureau: AbbVie, Amgen, AstraZeneca Celltrion, Eli Lilly, Fresenius Kabi, GSK, Organon, Pfizer Inc and Sandoz, Consultant of: AbbVie, Amgen, AstraZeneca Celltrion, Eli Lilly, Fresenius Kabi, GSK, Organon, Pfizer Inc and Sandoz, Joseph C Cappelleri Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Megan Hoang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Jade Moser: None declared, Cassandra Kinch Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Meriem Kessouri Shareholder of: Pfizer Inc, Employee of: Pfizer Inc.